AU2009212097B2 - Methods and compositions for treating inflammatory bowel disease - Google Patents

Methods and compositions for treating inflammatory bowel disease Download PDF

Info

Publication number
AU2009212097B2
AU2009212097B2 AU2009212097A AU2009212097A AU2009212097B2 AU 2009212097 B2 AU2009212097 B2 AU 2009212097B2 AU 2009212097 A AU2009212097 A AU 2009212097A AU 2009212097 A AU2009212097 A AU 2009212097A AU 2009212097 B2 AU2009212097 B2 AU 2009212097B2
Authority
AU
Australia
Prior art keywords
rifabutin
clofazimine
clarithromycin
auco
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009212097A
Other languages
English (en)
Other versions
AU2009212097A1 (en
Inventor
Thomas Julius Borody
Patrick Gosselin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RED HILL BIOPHARMA Ltd
Original Assignee
RED HILL BIOPHARMA Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RED HILL BIOPHARMA Ltd filed Critical RED HILL BIOPHARMA Ltd
Publication of AU2009212097A1 publication Critical patent/AU2009212097A1/en
Assigned to RED HILL BIOPHARMA LTD reassignment RED HILL BIOPHARMA LTD Request for Assignment Assignors: GIACONDA LIMITED
Application granted granted Critical
Publication of AU2009212097B2 publication Critical patent/AU2009212097B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2009212097A 2008-02-08 2009-02-05 Methods and compositions for treating inflammatory bowel disease Active AU2009212097B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6514408P 2008-02-08 2008-02-08
US61/065,144 2008-02-08
PCT/AU2009/000129 WO2009097651A1 (en) 2008-02-08 2009-02-05 Methods and compositions for treating inflammatory bowel disease

Publications (2)

Publication Number Publication Date
AU2009212097A1 AU2009212097A1 (en) 2009-08-13
AU2009212097B2 true AU2009212097B2 (en) 2013-06-13

Family

ID=40951740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009212097A Active AU2009212097B2 (en) 2008-02-08 2009-02-05 Methods and compositions for treating inflammatory bowel disease

Country Status (18)

Country Link
US (10) US8343511B2 (enExample)
EP (2) EP2247291B1 (enExample)
JP (1) JP5572872B2 (enExample)
AU (1) AU2009212097B2 (enExample)
CA (1) CA2714043C (enExample)
CY (1) CY1121465T1 (enExample)
DK (1) DK2247291T3 (enExample)
ES (1) ES2708087T3 (enExample)
HR (1) HRP20190045T1 (enExample)
HU (1) HUE041305T2 (enExample)
IL (1) IL207420A (enExample)
NZ (1) NZ587250A (enExample)
PL (1) PL2247291T3 (enExample)
PT (1) PT2247291T (enExample)
SI (1) SI2247291T1 (enExample)
TR (1) TR201819940T4 (enExample)
WO (1) WO2009097651A1 (enExample)
ZA (1) ZA201005735B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587250A (en) 2008-02-08 2011-12-22 Red Hill Biopharma Ltd Methods and compositions for treating inflammatory bowel disease
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
CA2883443C (en) 2012-08-30 2021-01-12 James Sacchettini Compositions and methods for drug-sensitization or inhibition of a cancer cell
WO2015123392A1 (en) * 2014-02-14 2015-08-20 The Texas A&M University System Compositions and methods for inhibition of angiogenesis and lymphangiogenesis
EP3145510B8 (en) * 2014-05-22 2021-10-27 Kuenstner, John, Todd Treatment of diseases using combination of ultraviolet blood irradiation and antibiotics
BR112018003232A2 (pt) * 2015-10-06 2018-09-25 Redhill Biopharma Ltd terapias de combinação para tratamento de câncer
CN107202848B (zh) * 2017-07-24 2022-11-15 浙江华海药业股份有限公司 一种氯法齐明的液相色谱分析方法
EP3676580A4 (en) * 2017-08-29 2021-05-26 Weightrx Inc. SYSTEM AND PROCESS FOR AUTOMATED MONITORING OF CONSUMABLES
AU2020344214A1 (en) * 2019-09-12 2022-04-21 BioVersys AG Antibiotic combination therapies
CA3187031A1 (en) * 2020-06-30 2022-01-06 Redhill Biopharma Ltd. Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
WO2022204375A1 (en) * 2021-03-25 2022-09-29 The Regents Of The University Of Michigan Compositions and methods for detecting, preventing, and treating disturbed microbiota-immune homeostasis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043667A1 (en) * 1997-04-01 1998-10-08 Borody Thomas J Methods and compositions for treating inflammatory bowel disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
NZ587250A (en) 2008-02-08 2011-12-22 Red Hill Biopharma Ltd Methods and compositions for treating inflammatory bowel disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043667A1 (en) * 1997-04-01 1998-10-08 Borody Thomas J Methods and compositions for treating inflammatory bowel disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BORODY, T. J. et al. "Treatment of severe Crohn's disease using antimycobacterial triple therapy - approaching a cure?" Digestive and Liver Disease, January 2002, vol. 34, no. 1, pages 29-38. *
DUBE, M.P. et al. "Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS." Clinical Infectious Diseases, January 1999, vol. 28, pages 136-138. *
SELBY, W. et al. "Two-tear combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease." Gastroenterology, 2007, vol. 132, pages 2313-2319. *
YAJKO, D.M. et al. al. Antimicrobial Agents and Chemotherapy, March 1996, vol. 40, no. 3, pages 743-749. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof

Also Published As

Publication number Publication date
SI2247291T1 (sl) 2019-03-29
TR201819940T4 (tr) 2019-01-21
PL2247291T3 (pl) 2019-05-31
CA2714043A1 (en) 2009-08-13
US20140315841A1 (en) 2014-10-23
NZ587250A (en) 2011-12-22
US20110059136A1 (en) 2011-03-10
ES2708087T3 (es) 2019-04-08
CA2714043C (en) 2016-11-08
US10765691B2 (en) 2020-09-08
US20200030352A1 (en) 2020-01-30
HUE041305T2 (hu) 2019-05-28
IL207420A0 (en) 2010-12-30
US20170232028A1 (en) 2017-08-17
ZA201005735B (en) 2011-10-26
CY1121465T1 (el) 2020-05-29
US9314477B2 (en) 2016-04-19
EP3391882A1 (en) 2018-10-24
US11090326B2 (en) 2021-08-17
IL207420A (en) 2015-09-24
DK2247291T3 (en) 2019-01-21
US20130237488A1 (en) 2013-09-12
US20200206253A1 (en) 2020-07-02
EP2247291A4 (en) 2011-04-13
US9072763B2 (en) 2015-07-07
US20190060343A1 (en) 2019-02-28
HRP20190045T1 (hr) 2019-03-08
US10434114B2 (en) 2019-10-08
WO2009097651A1 (en) 2009-08-13
US9198926B2 (en) 2015-12-01
US10143702B2 (en) 2018-12-04
EP2247291A1 (en) 2010-11-10
JP2011511012A (ja) 2011-04-07
US10105379B2 (en) 2018-10-23
AU2009212097A1 (en) 2009-08-13
US20140243279A1 (en) 2014-08-28
PT2247291T (pt) 2019-02-01
EP2247291B1 (en) 2018-12-05
US20160228464A1 (en) 2016-08-11
US20180125872A1 (en) 2018-05-10
US8343511B2 (en) 2013-01-01
JP5572872B2 (ja) 2014-08-20

Similar Documents

Publication Publication Date Title
AU2009212097B2 (en) Methods and compositions for treating inflammatory bowel disease
HK1226940A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
SK284539B6 (sk) Použitie nikotínu, farmaceutické kompozície a farmaceutický kombinačný produkt
Kirch et al. Dose‐dependence of the nifedipine‐digoxin interaction?
WO2015011189A1 (en) A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
HK1262346A1 (en) Compositions comprising rifabutin, clarithromycin, and clofazimine
Challenor et al. Food and nifedipine pharmacokinetics
Choi et al. The effect of food on the relative bioavailability of fadrozole hydrochloride
CA2632198C (en) Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
Souza et al. Evaluation of the relative bioavailability between two formulations of olmesartan medoxomil 40mg, in orodispersible tablet form and coated tablet form, in healthy participants of both sexes
Isnawati et al. Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteers
Rafiq et al. In vitro and in vivo evaluation of two sustained release formulations of diltiazem HCl
Simicevic et al. Lack of effect of food on the bioavailability of oral azithromycin tablets
Leucuta et al. Relative bioavailability of different oral sustained release oxprenolol tablets
Mahesh et al. Pharmacokinetic and Bioequivalence Com-parison Between Lumefantrine Tablets 480mg: an Open Label, Balanced, Random-ized-sequence, Single-dose, Two-period Crossover Study in Healthy Male Volun-teers

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RED HILL BIOPHARMA LTD

Free format text: FORMER APPLICANT(S): GIACONDA LIMITED

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BORODY, THOMAS JULIUS AND GOSSELIN, PATRICK .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BORODY, THOMAS JULIUS AND GOSSELIN, PATRICK